12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Company News  |  Deals

EpiCept, Immune Pharmaceuticals deal

The companies announced they will merge in a stock deal. After the deal, which is expected to close next quarter, former EpiCept shareholders will own 22.5% of the combined company, which will be named Immune Pharmaceuticals Inc. The company will have dual headquarters in Herzliya-Pituach and the New York City area and said it will focus on developing antibodies for cancer and inflammatory diseases. Immune's CEO Daniel...

Read the full 315 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >